Hypertensive disease
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Chronic infusion of Ang I resulted in the development of hypertension (P < 0.001), and augmented intrarenal chymase gene expression (P < 0.05), angiotensinogen protein level (P < 0.001) and Ang II content (P < 0.01) in salt-treated mice.
|
30137655 |
2018 |
Hypertensive disease
|
0.330 |
GeneticVariation
|
group |
BEFREE |
Single nucleotide polymorphisms (SNPs, n = 114) in nine RAAS-related genes (AGT, REN, ACE, ACE2, AGTR1, CYP11B2, NR3C2, MAS1, and CMA1) were assessed for their correlation with blood pressure and hypertension using genotype data of 8842 individuals from the Korea Association Resource subject pool.MAJOR FINDINGS.
|
21342026 |
2011 |
Hypertensive disease
|
0.330 |
Biomarker
|
group |
BEFREE |
It has been suspected that the mast cell chymase gene (CMA1) is important for the generation of angiotensin II and therefore might be associated with the pathogenesis of hypertension.
|
15106801 |
2004 |
Hypertensive disease
|
0.330 |
Biomarker
|
group |
CTD_human |
Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy.
|
14620933 |
2003 |
Left Ventricular Hypertrophy
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril.
|
15788353 |
2005 |
Left Ventricular Hypertrophy
|
0.310 |
Biomarker
|
disease |
CTD_human |
Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy.
|
14620933 |
2003 |
Pulmonary Fibrosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chymase is activated in the pulmonary inflammation and fibrosis induced by paraquat in hamsters.
|
15297733 |
2004 |
Alveolitis, Fibrosing
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chymase is activated in the pulmonary inflammation and fibrosis induced by paraquat in hamsters.
|
15297733 |
2004 |
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes.
|
15337505 |
2005 |
Granuloma
|
0.200 |
Biomarker
|
phenotype |
RGD |
Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5.
|
15723097 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness.
|
31395464 |
2020 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that the oncogene Multiple Copies in T-cell Malignancy 1 (MCT-1/MCTS1) expression is a new poor-prognosis marker in patients with aggressive breast cancers.
|
30885232 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Luciferase assay and q-RT-PCR showed MCT1 is a direct target of miR-124 in both breast cancer cell lines and patient specimens.
|
31367191 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that the oncogene Multiple Copies in T-cell Malignancy 1 (MCT-1/MCTS1) expression is a new poor-prognosis marker in patients with aggressive breast cancers.
|
30885232 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast-cancer cell glycometabolic coupling ring mediated by monocarboxylate transporter (MCT) 4 and MCT1 was then proved in the tumor microenvironment.
|
30698991 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An xenograft mice model was established and evaluated for the in vivo tumor therapeutic effects of MCT1 inhibitor plus microRNA-124 treatments.
|
31367191 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast-cancer cell glycometabolic coupling ring mediated by monocarboxylate transporter (MCT) 4 and MCT1 was then proved in the tumor microenvironment.
|
30698991 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumour development and progression.
|
31827199 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo <sup>13</sup> C MRSI studies of orthotopic tumors in mice also showed a significant 52% decrease in hyperpolarized [1-<sup>13</sup> C]Lac/Pyr when comparing vorinostat-treated U87 GBM tumors with controls, and, as in the cell studies, this metabolic finding was associated with increased MCT1 and MCT4 expression in HDAC-inhibited tumors.
|
30561869 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCT1 expression was significantly increased in HPV-negative tumours, and inhibition suppressed tumour cell invasion, colony formation and promoted radiosensitivity.
|
30655616 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that expression of MCT1 in the NHL tumour compartment was significantly associated with a poor clinicopathological profile.
|
30790227 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As mammary tumor progression was promoted by oncogenic MCT-1 activation, tumor-promoting M2 macrophages were enriched in TME, whereas M2 macrophages were decreased and tumor-suppressive M1 macrophages were increased as the tumor was repressed via MCT-1 knockdown.
|
30885232 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Monocarboxylate transporters 1 and 4 (MCT1 and MCT4) are involved in tumor development and progression.
|
31017677 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Background</i>: Monocarboxylate transport protein 1 (MCT1) has been defined as a critical regulator in tumor energy metabolism, but bibliometric analysis of MCT1 research is rare.
|
30934693 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Luciferase assay and q-RT-PCR showed MCT1 is a direct target of miR-124 in both breast cancer cell lines and patient specimens.
|
31367191 |
2019 |